BIOMAT Database Logo BIOMAT Database Logo

Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. 1996

N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Rudolph Magnus Institute of Neurosciences, Department of Neurology, Utrecht, The Netherlands.

In an open prospective study, we analyzed the effect of cyclophosphamide (300 mg/m2 body surface daily for 4 days) combined with prednisone (40 mg/m2 body surface daily for 5 days) at 4-week intervals during 6 months in 16 patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). Eleven patients had an IgM-MGUS and five an IgG-MGUS. During a follow-up period of 3 years, eight patients had improvement and six patients stabilized, based on quantitative neurologic examination, the Rankin disability scale, and electrophysiologic studies. These 14 patients had neuropathy with demyelinating and axonal features. One patient with a purely axonal neuropathy had deterioration despite therapy. One other patients developed severe leukopenia as side effect of cyclophosphamide, necessitating withdrawal of treatment. A difference in response was not present in patient with IgM- or IgG-MGUS, nor in patients with or without autoantibodies against myelin-associated glycoprotein. Nine patients had a bone marrow biopsy before and 1 year after treatment. In eight patients, the monoclonal lymphoid IgM or plasma cell IgG infiltration decreased, while in four the monoclonality disappeared after treatment. In the patient who had neurologic deterioration, repeated bone marrow biopsy showed deposits of amyloid. In conclusion, short-term treatment with intermittent cyclophosphamide and prednisone may have a long-term favorable effect in patients with demyelinating polyneuropathy associated with MGUS.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010265 Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. Gammapathy, Monoclonal,Gammopathy, Monoclonal,Monoclonal Gammopathies,Paraimmunoglobulinemia,Paraimmunoglobulinemias,Paraproteinemia,Plasma Cell Dyscrasias,Monoclonal Gammapathies,Monoclonal Gammopathy,Cell Dyscrasia, Plasma,Dyscrasia, Plasma Cell,Monoclonal Gammapathy,Plasma Cell Dyscrasia
D011115 Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance. Polyneuropathy, Acquired,Polyneuropathy, Critical Illness,Polyneuropathy, Familial,Polyneuropathy, Inherited,Polyneuropathy, Motor,Acquired Polyneuropathies,Acquired Polyneuropathy,Critical Illness Polyneuropathies,Critical Illness Polyneuropathy,Familial Polyneuropathies,Familial Polyneuropathy,Inherited Polyneuropathies,Inherited Polyneuropathy,Motor Polyneuropathies,Motor Polyneuropathy,Polyneuropathies, Acquired,Polyneuropathies, Critical Illness,Polyneuropathies, Familial,Polyneuropathies, Inherited,Polyneuropathies, Motor,Polyneuropathy
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
[Polyneuropathy associated with monoclonal gammopathy of undetermined significance].
October 2012, Ugeskrift for laeger,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance.
January 1993, Muscle & nerve,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance.
October 1993, Muscle & nerve,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.
November 1991, The New England journal of medicine,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Peripheral polyneuropathy and monoclonal gammopathy of undetermined significance.
July 1985, Journal of neurology, neurosurgery, and psychiatry,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance.
February 1994, Acta neurologica Scandinavica,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS).
January 1999, Journal of clinical apheresis,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Papuloerythroderma associated with monoclonal gammopathy of undetermined significance.
April 2009, The Journal of dermatology,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
January 2018, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti,
N C Notermans, and H M Lokhorst, and H Franssen, and Y Van der Graaf, and L L Teunissen, and F G Jennekens, and L H Van den Berg, and J H Wokke
Monoclonal Gammopathy of Undetermined Significance-associated Scleromyxoedema.
January 2019, Indian dermatology online journal,
Copied contents to your clipboard!